Leadman announced that the recombinant B-group meningococcal vaccine developed by Beijing Xiansheng Xiangrui Biological Products Co., Ltd., a subsidiary of the company, has obtained the “Drug Clinical Trial Approval Notice” from the State Drug Administration and agreed to carry out clinical trials to prevent infectious encephalomyelitis caused by Neisseria meningitidis group B. The vaccine uses a multi-component recombinant protein technology route and an Escherichia coli expression system, and is registered as a prophylactic biological product 2.2.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.